HUNENBERG, Switzerland--(BUSINESS WIRE)--Alcon, Inc. (NYSE: ACL) announced today that it has executed a new agreement and broadened an existing agreement with two different companies to expand its products under development. Alcon entered into a licensing agreement with GlaxoSmithKline (“GSK”) for global ophthalmic rights to cilomilast, a phosphodiesterase IV inhibitor. In addition to this new agreement, Alcon expanded its existing drug research alliance with Origenis GmbH with a focus on the discovery and development of the small molecules that might one day have a role in the treatment of eye diseases. Both agreements were signed by Alcon’s affiliate, Alcon Research, Ltd.
